Articles tagged with Heart Failure
A large clinical trial has identified empagliflozin as a treatment option for heart failure with preserved ejection fraction, reducing risk of hospitalization or death by 21 percent. The drug also showed fewer symptoms and mild side effects.
A study published in the Journal of the American Heart Association found that people with peripheral artery disease (PAD) living in poor or Black metropolitan areas have higher amputation rates. The analysis also noted significant disparities in healthcare access and quality among different racial and socioeconomic groups.
Researchers investigated sarpogrelate, an approved antiplatelet medication, for its potential to treat heart failure. Sarpogrelate suppressed cardiomyocyte hypertrophy and the development of heart failure in mice, suggesting it may be an effective low-cost agent for heart failure therapy.
A new preclinical study validates the spleen's role in cardiac healing and suggests targeting S1P as a potential treatment for heart failure. The study discovered interactions between S1P and the heart during transition from acute to chronic heart failure.
A meta-analysis of 19 randomized controlled trials found that ultrafiltration is superior to control treatments for weight loss (WMD 1.24 kg) and fluid removal (WMD 1.55 L), but associated with increased serum creatinine levels. The use of ultrafiltration in ADHF patients is efficient for fluid management but less safe renally.
A recent study published in European Heart Journal: ESC heart failure shows that increased oxidative stress during exercise adversely affects heart failure prognosis. Tailoring exercise therapy to individual patients based on their level of oxidative stress may be more effective than conventional exercise therapies.
A study published in PNAS uses CRISPR technology to understand how genetic mutations cause hypertrophic cardiomyopathy. The research found that specific mutations can lead to changes in the movement of myosin proteins, which are essential for heart contraction. This new understanding has implications for preventing and treating HCM.
A new study found that 44% of micro-arteries from patients had abnormal myogenic tone, associated with excessive caldesmon presence and poor cell alignment. This abnormality affects blood supply within the heart and other organs, impacting quality of life and life expectancy.
A study published in Scientific Reports describes the putative molecular regulators of reductive stress — a microRNA network. The researchers identified a subset of miRNAs that appeared to be direct and dose-dependent targets of Nrf2, and thus putative regulators of reductive stress.
Research found that patients with ICDs who increased physical activity outside of cardiac rehab experienced fewer hospitalizations and lower death rates, with every 10 minutes of added activity reducing death risk by 1.1%
The European Society of Cardiology has announced the ESC Congress 2021 press programme, featuring live hot line sessions and embargoed press conferences. The programme will showcase new data on heart failure, valvular heart disease, cardiac arrest, hypertension, and atrial fibrillation.
A recent study published by the European Society of Cardiology found that older patients with heart failure are less likely to receive recommended therapies and dosages compared to their younger counterparts. The study analyzed data from the Swedish Heart Failure Registry and found that age was independently associated with undertreatm...
A recent study found that heart attack patients during the pandemic were more likely to experience heart failure, with delays in treatment resulting in poorer outcomes. The study also noted a significant increase in post-treatment pump function decline and hospital admissions for decompensated heart failure.
A large cohort study found that patients with heart failure are more likely to develop cancer compared to those without. The incidence of cancer was significantly higher among heart failure patients, particularly for certain types of cancer such as lip, oral cavity, and pharynx cancers.
Researchers at Gladstone Institutes have discovered a master switch for fibrosis in the heart, which they believe could be used to treat and prevent heart failure. The study suggests that blocking this gene, MEOX1, could prevent fibrosis in other organs as well.
A novel lncRNA, Caren, has been identified as a potential therapeutic target for heart failure. It enhances energy production in cardiomyocytes and inhibits the activation of the ATM protein, which accelerates heart failure severity. Increasing Caren expression may inhibit heart failure progression.
Studies of people with RA show a decline in dementia risk over time, from 12.7% to 6.2% between the 1980s and 2000s. Heart failure risks also decrease, with no excess risk seen in 2000s compared to general population.
A clinical trial conducted at the University of Louisville showed that cell therapy using cells derived from a patient's own bone marrow and heart improved quality of life and reduced major adverse cardiac events. The treatment resulted in a significant reduction in hospitalizations and improved outcomes for patients with heart failure.
A new study found that individuals with metabolically healthy obesity (MHO) are at higher risk of developing diabetes, heart diseases, strokes, and respiratory diseases. Despite having a normal metabolic profile, MHO individuals face increased mortality rates compared to those with normal weight but unhealthy metabolism.
A new analysis found that post-heart transplant survival among older patients is on par with younger recipients. The study included 37,135 patients and showed a significant improvement in mortality rates after adjusting for other factors, suggesting that advanced age should not be a contraindication for heart transplantation.
A new study published in the Journal of the American Geriatrics Society found that heart transplant surgery has a similar mortality rate for adults aged 18-69 and 70+, with only minor differences in stroke risk and donor hearts. Advanced age alone should not prevent people from being considered as candidates for heart transplants.
Research found nearly 20% of patients with unexplained sudden cardiac death carried rare genetic variants that raised their risk. Genetic screening may have prevented deaths if doctors knew about the genetic predisposition to heart disease.
Researchers have developed a new AI-powered diagnostic tool using electrocardiograms (ECGs) to diagnose coronary artery disease, myocardial infarction, and congestive heart failure. The tool achieved an accuracy of over 98.5% in classifying patients' ECG signals.
A new physiological measurement of heart function, PAPP, has been shown to identify high-risk patients with systolic heart failure or pulmonary hypertension. This monitoring technology can reduce the risk of death by 46% annually in patients with low PAPPs.
A study found that using ultrasound to monitor lung congestion in hemodialysis patients with high cardiovascular risk improved patient outcomes. The technique reduced episodes of decompensated heart failure and cardiovascular events by 37% and 63%, respectively.
A study by University of Exeter researchers found a 40% decline in patients admitted with heart attacks and a 30-40% decrease in use of cardiology services during the pandemic. However, there has been an increase in home-based rehabilitation options, suggesting a need for more evidence-based programs to be rolled out.
The Heart Failure 2021 congress showcases the latest evidence on preventing and managing heart failure, including the impact of COVID-19 and digital health. Researchers will present data on improving quality of life for patients with heart failure through medication, physical activity, diet, and implantable devices.
Researchers found that excess pericardial fat increases the risk of heart failure, even after adjusting for established risk factors. High pericardial fat volume was associated with a double increase in risk for women and a 50% increase for men, according to the study published in the Journal of the American College of Cardiology.
A team of scientists from Loyola University Chicago's Stritch School of Medicine have discovered a critical component for renewing the heart's molecular motor, which breaks down in heart failure. Restoring BAG3 levels could strengthen the heart as a potential treatment for heart failure.
Brigham cardiologists presented findings on IL-6 inhibitors, SGLT1/2 inhibitors and statin drugs in COVID-19 patients, highlighting potential benefits and limitations. The studies suggest new therapeutic options for preventing future cardiovascular events and improving outcomes for patients with heart failure and kidney disease.
The LIFE trial found that sacubitril/valsartan combination therapy did not improve health outcomes for patients with severe heart failure with reduced ejection fraction. The study showed that valsartan alone was more effective in reducing hyperkalemia and clinical outcomes.
Researchers found that sotagliflozin reduced the risk of death or worsening heart failure by 22-43% in patients with both diabetes and heart failure. The medication showed significant benefits across various patient subgroups, including those with preserved ejection fraction.
A randomized controlled trial found that an additional auditing and feedback program on hospital care for heart failure patients did not improve outcomes, including reduced rehospitalization and death rates. The study's lead author suggests future interventions may employ digital tools or focus on care delivery outside the hospital.
The experimental drug omecamtiv mecarbil significantly reduces hospitalizations for patients with severe heart failure and low ejection fractions. It offers improved benefits over current medications, especially in those with more severely impaired hearts.
Early-phase trial found pirfenidone significantly reduced a marker of heart muscle scarring compared to placebo in patients with preserved ejection fraction. The study suggests that fibrosis is an effective treatment target and could lead to personalized approaches to prevent or reverse scarring.
Research suggests that the type of heart failure a patient has may influence which approach is optimal for treating atrial fibrillation (AFib). A study found that rhythm control may be especially beneficial for patients with reduced ejection fraction, but more research is needed to confirm this trend.
A new clinical trial found that a tailored, earlier heart failure rehabilitation program improved frailty, depression, and overall quality of life in hospitalized patients. The study showed significant gains in physical functioning and self-perception of health status.
A novel rehabilitation program, REHAB-HF, improved physical function, balance, mobility, strength, and endurance in hospitalized older patients with acute heart failure. The program, tailored to individual needs and starting early in the hospital stay, showed significant gains regardless of ejection fraction.
A novel 12-week physical rehabilitation program tailored to address specific physical impairments in older heart failure patients improved physical functioning, quality of life, and depression. However, participation did not significantly reduce rehospitalizations during the six-month follow-up period.
The PARADISE-MI trial found sacubitril/valsartan to be well-tolerated and associated with a trend toward improvement in secondary endpoints. However, it did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril.
Elevated levels of O-GlcNAc can make mice more prone to heart failure, but lowering them restores normal risk and function. The findings suggest targeting the O-GlcNAc pathway could help prevent or stop human heart failure.
A study published in the European Journal of Preventive Cardiology found that nearly one in four heart failure patients experience depression or anxiety, compared to 23% of breast cancer patients, 22% of prostate cancer patients, and 15% of digestive organ cancer patients. Heart failure patients are also at a higher risk of developing ...
A preclinical study by USF Health found that blocking lipoxygenase with a synthetic inhibitor alters the innate inflammatory response, delaying heart tissue repair after cardiac injury. The study suggests that preserving lipoxygenase is crucial for maintaining immune-mediated acute inflammation and preventing heart failure.
A study by the American College of Cardiology found that nonsmokers exposed to secondhand smoke have a 35% increased risk of developing heart failure. The association was strongest in men and among those with previous heart conditions, highlighting the need for education and stringent smoke-free policies.
A new genetic mutation found in African Americans significantly increases risk of atrial fibrillation and heart failure, prompting researchers to recommend genetic testing for this population. The study also identifies a potential link between a newly discovered gene and early-onset AFib.
A new Mount Sinai study found that patients hospitalized with COVID-19 have a small but significant risk of developing heart failure, even without a previous history of heart disease or cardiovascular risk factors. The study's findings may prompt clinicians to monitor for signs of congestive heart failure more closely in these patients.
A study published in Circulation found four new genetic variants associated with peripartum cardiomyopathy, a rare condition characterized by weakened heart muscle. The research suggests that these genetic mutations may be linked to non-ischemic dilated cardiomyopathy, a disease affecting middle-aged men and women.
A 21-year-old's excessive energy drink consumption has been linked to heart failure, highlighting the potential risks of these drinks. The case report warns of the need for clear warnings about the cardiovascular dangers of large-scale energy drink consumption.
A University of Alabama at Birmingham study found that cytosine-p-guanine, or CpG, methylation of the DNA in the heart is associated with differences in heart-failure outcomes. The researchers also discovered that African American patients had higher rates of death from heart failure compared to Caucasian patients, suggesting a link be...
Scientists at Temple University and Case Western Reserve University will explore the role of nitric oxide in controlling the beta-adrenergic receptor system, a key player in heart function. The insights gained could lead to new therapies for congestive heart failure.
A study published in JACC reveals that clonal hematopoiesis, a phenomenon where acquired DNA mutations accelerate heart failure progression, is an independent risk factor. The presence of specific mutant clones, including those with TET2 and DNMT3A mutations, increases the risk of hospitalization and death from heart failure.
Researchers at Temple University Health System discovered that blocking GRK5's nuclear activity can prevent cardiac hypertrophy and reduce maladaptive effects in the heart. The findings offer exciting avenues for developing therapies to prevent heart failure.
A new Northwestern Medicine study reveals significant disparities in heart failure mortality rates between rural and urban areas, with rural areas experiencing higher death rates. The research also highlights race disparities among Black adults under 65 years old.
A mouse study finds that treatment with MCB-613 repairs heart tissue after a severe heart attack, preventing damage and scarring. The molecule decreases inflammation and increases heart function, offering hope for effective treatments to prevent heart failure.
A new study by scientists at Temple University identifies a promising novel therapeutic strategy targeting G protein-coupled receptor kinase 5 (GRK5) in the heart. Reducing GRK5 levels improves survival following heart attack in mice, suggesting that GRK5 inhibition may be a viable treatment option for human patients.
Nationwide analysis reveals adults in rural counties experience higher heart failure-related death rates compared to urban counterparts, with greater increases for younger adults. Socioeconomic factors and clinical risk factors contribute to the urban-rural divide, prompting a need for targeted health and economic policy efforts.
Researchers found that heart failure causes impaired gene activity in the brain's memory center, leading to cognitive deficits. A specific drug alleviated mental deficits in mice, suggesting potential approaches for therapies.
Researchers found that limiting fat release from fat cells during heart failure can reduce inflammation and improve cardiac function. In a study, mice treated with a drug blocking fat release showed better outcomes than control groups.
Analysis of 448 patients with heart failure reveals 20.3% readmitted within 30 days and 60.9% within 1 year, primarily due to worsening heart failure conditions.
A genetic study found that increased Polynesian ancestry is linked to a higher risk of obesity, Type-2 diabetes, and heart failure in Native Hawaiians. The study suggests both genetic and lifestyle factors contribute to these disease risks.